ArticleEJHaem2021
Blood group type A secretors are associated with a higher risk of COVID-19 cardiovascular disease complications.
Article in EJHaem, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Detailed stratified GWAS analysis for severe COVID-19 in four European populations.Human molecular genetics · 2022Pooled it
- The Investigation of the Distribution of ABO/Rh Blood Group in Hospitalized COVID-19 Patients and Its Association With Disease Severity, Clinical Outcomes, Lab Tests, and Radiologic Findings.Health science reports · 2025Article
- COVID-19 and blood group-related antigens: can natural anti-carbohydrate antibodies provide innate protection from symptomatic SARS-CoV-2 infection?Frontiers in medicine · 2025Article
- Investigating ABO Blood Groups and Secretor Status in Relation to SARS-CoV-2 Infection and COVID-19 Severity.Journal of personalized medicine · 2024Review
- Association of ABO and Rhesus blood groups with severe outcomes from non-SARS-CoV-2 respiratory infection: A prospective observational cohort study in Bristol, UK 2020-2022.British journal of haematology · 2024Observational
- Association between ABO blood groups and SARS-CoV-2 infection in blood donors of Puglia region.Annals of hematology · 2023Observational
- Viral load at hospitalization is an independent predictor of severe COVID-19.European journal of clinical investigation · 2023Article
- A large cohort study of the effects of Lewis, ABO, 13 other blood groups, and secretor status on COVID-19 susceptibility, severity, and long COVID-19.Transfusion · 2023Article
- mGWAS-Explorer: Linking SNPs, Genes, Metabolites, and Diseases for Functional Insights.Metabolites · 2022Article
- Association of ABO blood group with in-hospital adverse outcome and long term persistent symptoms of COVID-19 infection: A single-center longitudinal observational study.Health science reports · 2022Article
- Human Milk Oligosaccharides: Potential Applications in COVID-19.Biomedicines · 2022Review
- FUT2 gene as a genetic susceptible marker of infectious diseases: A Review.International journal of molecular epidemiology and genetics · 2022Review
- ABO Blood Groups and the Incidence of Complications in COVID-19 Patients: A Population-Based Prospective Cohort Study.International journal of environmental research and public health · 2021Article
- Blood group type A secretors are associated with a higher risk of COVID-19 cardiovascular disease complications.EJHaem · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The SARS-CoV-2 virus causes COVID-19, an infection capable of causing severe disease and death but which can also be asymptomatic or oligosymptomatic. We investigated whether ABO blood group or secretor status was associated with COVID-19 severity. We investigated secretor status because expression of ABO glycans on secreted proteins and non-erythroid cells are controlled by a fucosyltransferase (FUT2), and inactivating FUT2 mutations result in a non-secretor phenotype which protects against some viral infections. Data combined from healthcare records and our own laboratory tests (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.